16.86
4.91%
0.785
Precedente Chiudi:
$16.08
Aprire:
$16.08
Volume 24 ore:
148.56K
Relative Volume:
0.23
Capitalizzazione di mercato:
$201.94M
Reddito:
$1.54M
Utile/perdita netta:
$-38.70M
Rapporto P/E:
-1.5332
EPS:
-11
Flusso di cassa netto:
$-36.86M
1 W Prestazione:
-3.87%
1M Prestazione:
-4.53%
6M Prestazione:
-62.68%
1 anno Prestazione:
+301.67%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Nome
Corbus Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
617-963-0103
Indirizzo
500 RIVER RIDGE DRIVE, NORWOOD, MA
Confronta CRBP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
CRBP | 16.87 | 201.94M | 1.54M | -38.70M | -36.86M | -11.00 |
VRTX | 449.33 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 749.22 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.35 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.58 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.96 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2020-09-08 | Downgrade | BTIG Research | Buy → Neutral |
2020-09-08 | Downgrade | Jefferies | Buy → Hold |
2020-09-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2020-09-08 | Downgrade | ROTH Capital | Buy → Neutral |
2020-07-07 | Iniziato | ROTH Capital | Buy |
2020-06-17 | Iniziato | BTIG Research | Buy |
2020-03-26 | Iniziato | Nomura | Buy |
2019-04-05 | Iniziato | Jefferies | Buy |
2019-03-20 | Iniziato | Oppenheimer | Outperform |
2019-01-11 | Reiterato | Cantor Fitzgerald | Overweight |
2018-12-26 | Iniziato | H.C. Wainwright | Buy |
2018-12-07 | Iniziato | RBC Capital Mkts | Outperform |
2018-10-24 | Iniziato | B. Riley FBR | Buy |
2018-01-19 | Iniziato | Raymond James | Outperform |
2017-12-14 | Reiterato | Cantor Fitzgerald | Overweight |
2017-11-08 | Reiterato | Noble Financial | Buy |
2017-09-29 | Ripresa | Noble Financial | Buy |
2017-03-30 | Reiterato | Cantor Fitzgerald | Overweight |
2016-11-15 | Reiterato | JMP Securities | Mkt Outperform |
2016-11-11 | Reiterato | Noble Financial | Buy |
Mostra tutto
Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference - GlobeNewswire
Corbus Pharmaceuticals to Present at Evercore HealthCONx Conference in December | CRBP Stock News - StockTitan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals director sets plan for stock sale - Investing.com India
(CRBP) Investment Report - Stock Traders Daily
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Update - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
OrbiMed Advisors LLC Acquires New Stake in Corbus Pharmaceuticals Holdings Inc - GuruFocus.com
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Corbus Pharmac - GuruFocus.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference - GlobeNewswire
Corbus Pharmaceuticals to Present at Jefferies London Healthcare Conference | CRBP Stock News - StockTitan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Brokers Set Expectations for CRBP Q1 Earnings - MarketBeat
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies - Seeking Alpha
We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates - TipRanks
Corbus Pharmaceuticals: Q3 Earnings Snapshot - CT Insider
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
(CRBP) On The My Stocks Page - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Corbus Pharmaceuti - GuruFocus.com
Corbus Pharmaceuticals' (CRBP) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 - The Manila Times
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $65.86 Consensus PT from Analysts - Defense World
Short Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Grows By 5.8% - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $65.86 Consensus Price Target from Brokerages - MarketBeat
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock? - Inkl
Up 174% In 2024, Is It Too Late To Buy This Breakout Biotech Stock? - Barchart
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
Oppenheimer maintains steady target on Corbus Pharmaceuticals By Investing.com - Investing.com UK
Corbus Pharmaceuticals Holdings Inc Azioni (CRBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):